medigraphic.com
Revista Médica Sinergia

2022, Number 02

Next >>

Revista Médica Sinergia 2022; 7 (02)

Treatment and prophylaxis of recurrent urinary infection in women

Pérez FT, Agüero MM, Troz PIP

Language: Spanish
References: 15
Page:
PDF size: 189.04 Kb.


ABSTRACT

Urinary tract infection is a common clinical entity, with a high prevalence worldwide and that involves a high financial cost to health systems. This disease occurs more frequently in women, and 50-80% of women in the general population are known to get at least one urinary tract infection in their whole life. In addition, the average of recurrence in women is 2.6 urinary infections per year, which makes the knowledge about the therapeutic strategies available for the management and prevention of these infections of the utmost importance. There are several therapies with high evidence for the prevention of recurrence of urinary tract infections, among these are continuous and postcoital antibiotic prophylaxis, oral vaccination and vaginal estrogen replacement in postmenopausal women. The collateral damage produced by antibiotic therapy and the appearance of growing problems such as antibiotic resistance must always be taken into account, this has generated new studies of non-antibiotic alternatives for the treatment and prophylaxis of recurrent urinary infections. While some results from these studies are promising, evidence is still lacking to make a firm recommendation on them. The objective of this article is to review recurrent urinary tract infection in women, considering its epidemiology, pathogenesis, treatment and prevention of recurrence, emphasizing this last two points.


REFERENCES

  1. Sihra N, Goodman A, Zakri R, Sahai A, Malde S. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat Rev Urol. 2018;15(12):750–76. Available from: https://pubmed.ncbi.nlm.nih.gov/30361493/

  2. Cai T. Recurrent uncomplicated urinary tract infections: definitions and risk factors. GMS Infect Dis. 2021;9:Doc03. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167371/

  3. Ennis SS, Guo H, Raman L, Tambyah PA, Chen SL, Tiong HY. Premenopausal women with recurrent urinary tract infections have lower quality of life. Int J Urol. 2018;25(7):684–9. Available from: https://onlinelibrary.wiley.com/doi/10.1111/iju.13698

  4. Huttner A, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frölich R, et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis. 2017;17(5):528–37. Available from:https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30108-1/fulltext#%20

  5. Solano Mora A, Solano Castillo A, Ramírez Vargas X. Actualización del manejo de infecciones de las vías urinarias no complicadas. Rev Medica Sinerg. 2020;5(2):e356. Available from: https://revistamedicasinergia.com/index.php/rms/article/view/356

  6. Valdevenito JP, Álvarez D. Infección urinaria recurrente en la mujer. Rev médica Clín Las Condes. 2018;29(2):222–31. Available from: https://www.elsevier.es/es-revista-revista- medica-clinica-las-condes-202-articulo-infeccion-urinaria-recurrente-mujer-S0716864018300282

  7. Kasper D, Fauci S, Hauser J, Longo D, Jameson L, Loscalzo J. Harrison TR. Principios de Medicina Interna; 20va Ed. Nueva York, Estados Unidos de América: McGraw-Hill Professional Publishing. p 968-976

  8. Jiménez Bermúdez JP, Carballo Solís KD, Chacón Jiménez NK. Manejo de infecciones del tracto urinario. Rev costarric salud pública. 2017;26(1):1–10. Available from: https://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S1409-14292017000100001

  9. Villarraga JDA, Parra JDI, Diaz DA, Cardenas AM, Chavarriaga J, Godoy MP. Guía de práctica clínica de infección de vías urinarias en el adulto. Urol Colomb. 2018;27(02):126–31. doi: 10.1055/s-0038-1660528

  10. Taha Neto KA, Nogueira Castilho L, Reis LO. Vacuna oral (OM-89) en la profilaxis de infección urinaria recurrente: una revisión sistemática realista con metaanálisis. Actas Urol Esp. 2016;40(4):203–8. Available from: https://www.elsevier.es/es-revista-actas-urologicas-espanolas-292-articulo-vacuna-oral-om-89-profilaxis-infeccion-S0210480615001679

  11. Abou Heidar NF, Degheili JA, Yacoubian AA, Khauli RB. Management of urinary tract infection in women: A practical approach for everyday practice [Internet]. Urology annals. Wolters Kluwer - Medknow; 2019 [cited 2019Nov23]. Available https://www.ncbi.nlm.nih.gov/pubmed/31649450

  12. Magistro G, Stief CG. Vaccine Development for Urinary Tract Infections: Where Do We Stand? [Internet]. European urology focus. U.S. National Library of Medicine; 2019 [cited 2019Nov24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30093359

  13. Akgül T, Karakan T. The role of probiotics in women with recurrent urinary tract infections [Internet]. Turkish journal of urology. Turkish Association of Urology; 2018 [cited 2019Nov24]. https://www.ncbi.nlm.nih.gov/pubmed/30487041

  14. Eldridge GR, Hughey H, Rosenberger L, Martin SM, Shapiro AM, D’Antonio E, et al. Safety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 study. Hum Vaccin Immunother. 2021;17(5):1262–70.

  15. Dobrohotova YE, Korotkikh IN, Kuzmenko AV, V KV, Gyaurgiev TA. The efficiency of probiotics in the prevention of recurrent lower urinary tract infections and bacterial vaginosis. Urologia. 2021;4_2021(4):30–4. Available from: https://pubmed.ncbi.nlm.nih.gov/34486272/




2020     |     www.medigraphic.com